Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies

Bacterial cellulose: Is it really a promising biomedical material?

Bacterial cellulose (BC) is currently considered a promising biomaterial due to its specific structure and properties. However, despite extensive research, questions about its fundamental properties, especially biocompatibility, remain. Thus, the purpose of this review is to analyze the results of in vivo trials from different areas of biomedicine, including wound healing, tissue engineering, drug delivery, and biomedical implants. The primary question guiding our review was "Why is bacterial cellulose still not used in clinical practice?" Analysis of the literature has shown that the results of in vivo studies often contradict each other. For example, BC caused and did not cause an immune response in an equal number of reviewed articles. Its efficacy in pure form generally does not differ significantly from that of materials already on the market. Conversely, BC may prove to be a valuable material in the long term, not because of its efficacy, but rather because of its affordability and ease of use. Additionally, challenges associated with immune reactions, long-term biocompatibility, and the necessity for standardized experimental protocols must be addressed. We expect that this review will encourage a more thoughtful investigation of BC to bring it into practical medicine.

Recent progress of multifunctional nanocellulose-based pharmaceutical materials: A review

In the pharmaceutical industry, ongoing research and development focus on discovering new drug formulations that align with regulatory approvals. Recently, innovative drug delivery systems have been used to maximize therapeutic efficacy with a precision of sustained drug delivery in the disease management system. Nanocellulose (NCs) synthesized from abundant cellulose, have attracted wide attention for potential pharmaceutical applications due to their unique properties, such as biocompatibility, high surface area-to-volume ratio, extensive drug loading and binding capacity, controlled drug release efficiency, strength, and availability with various treatments and modification ability. Nevertheless, research on nanocarriers (NCs) in the pharmaceutical field faces several limitations and challenges. Key areas requiring further exploration include chemical consumption, energy intensity, effluent management, recovery processes from acid hydrolysis, reaction times, ecotoxicology, and overall development progress. This overview provides the applications of emerging nanocellulose. It gives a clue on the synthesis of sustainable NCs related to their different sources, pre- and post-modifications of NCs, and key properties in pharmaceutical sectors. Furthermore, it gives an overview of the current advancements, life cycle analysis, biosafety, and key property performance with a summary of challenges and future perspectives.

Bacterial cellulose films for L-asparaginase delivery to melanoma cells

L-asparaginase (L-ASNase) is an enzyme that catalyzes the hydrolysis of L-asparagine to L-aspartic acid and ammonia and is used to treat acute lymphoblastic leukemia. It is also toxic to the cells of some solid tumors, including melanoma cells. Immobilization of this enzyme can improve its activity against melanoma tumor cells. In this work, the properties of bacterial cellulose (BC) and feasibility of BC films as a new carrier for immobilized L-ASNase were investigated. Different values of growth time were used to obtain BC films with different thicknesses and porosities, which determine the water content and the ability to adsorb and release L-ASNase. Fourier transform infrared spectroscopy confirmed the adsorption of the enzyme on the BC films. The total activity of adsorbed L-ASNase and its release were investigated for films grown for 48, 72 or 96 h. BC films grown for 96 h showed the most pronounced release as described by zero-order and Korsmayer-Peppas models. The release was characterized by controlled diffusion where the drug was released at a constant rate. BC films with immobilized L-ASNase could induce cytotoxicity in A875 human melanoma cells. With further development, immobilization of L-ASNase on BC may become a potent strategy for anticancer drug delivery to superficial tumors.

Protein Immobilization on Bacterial Cellulose for Biomedical Application

New carriers for protein immobilization are objects of interest in various fields of biomedicine. Immobilization is a technique used to stabilize and provide physical support for biological micro- and macromolecules and whole cells. Special efforts have been made to develop new materials for protein immobilization that are non-toxic to both the body and the environment, inexpensive, readily available, and easy to modify. Currently, biodegradable and non-toxic polymers, including cellulose, are widely used for protein immobilization. Bacterial cellulose (BC) is a natural polymer with excellent biocompatibility, purity, high porosity, high water uptake capacity, non-immunogenicity, and ease of production and modification. BC is composed of glucose units and does not contain lignin or hemicellulose, which is an advantage allowing the avoidance of the chemical purification step before use. Recently, BC-protein composites have been developed as wound dressings, tissue engineering scaffolds, three-dimensional (3D) cell culture systems, drug delivery systems, and enzyme immobilization matrices. Proteins or peptides are often added to polymeric scaffolds to improve their biocompatibility and biological, physical-chemical, and mechanical properties. To broaden BC applications, various ex situ and in situ modifications of native BC are used to improve its properties for a specific application. In vivo studies showed that several BC-protein composites exhibited excellent biocompatibility, demonstrated prolonged treatment time, and increased the survival of animals. Today, there are several patents and commercial BC-based composites for wounds and vascular grafts. Therefore, further research on BC-protein composites has great prospects. This review focuses on the major advances in protein immobilization on BC for biomedical applications.

Recent advancements in development and application of microbial cellulose in food and non-food systems

Microbial cellulose is a fermented form of very pure cellulose with a fibrous structure. The media rich in glucose or other carbon sources are fermented by bacteria to produce microbial cellulose. The bacteria use the carbon to produce cellulose, which grows as a dense, gel-like mat on the surface of the medium. The product was then collected, cleaned, and reused in various ways. The properties of microbial cellulose, such as water holding capacity, gas permeability, and ability to form a flexible, transparent film make it intriguing for food applications. Non-digestible microbial cellulose has been shown to improve digestive health and may have further advantages. It is also very absorbent, making it a great option for use in wound dressings. The review discusses the generation of microbial cellulose and several potential applications of microbial cellulose in fields including pharmacy, biology, materials research, and the food industry.

Production of Bacterial Exopolysaccharides: Xanthan and Bacterial Cellulose

Recently, degradable biopolymers have become increasingly important as potential environmentally friendly biomaterials, providing a wide range of applications in various fields. Bacterial exopolysaccharides (EPSs) are biomacromolecules, which due to their unique properties have found applications in biomedicine, foodstuff, textiles, cosmetics, petroleum, pharmaceuticals, nanoelectronics, and environmental remediation. One of the important commercial polysaccharides produced on an industrial scale is xanthan. In recent years, the range of its application has expanded significantly. Bacterial cellulose (BC) is another unique EPS with a rapidly increasing range of applications. Due to the great prospects for their practical application, the development of their highly efficient production remains an important task. The present review summarizes the strategies for the cost-effective production of such important biomacromolecules as xanthan and BC and demonstrates for the first time common approaches to their efficient production and to obtaining new functional materials for a wide range of applications, including wound healing, drug delivery, tissue engineering, environmental remediation, nanoelectronics, and 3D bioprinting. In the end, we discuss present limitations of xanthan and BC production and the line of future research.

Bacterial cellulose-based composites as vehicles for dermal and transdermal drug delivery: A review

In recent years, a significant amount of drugs have been taken orally, which are not as effective as desired. To solve this problem, bacterial cellulose-based dermal/transdermal drug delivery systems (BC-DDSs) with unique properties such as cell compatibility, hemocompatibility, tunable mechanical properties, and the ability to encapsulate various therapeutic agents with the controlled release have been introduced. A BC-dermal/transdermal DDS reduces first-pass metabolism and systematic side effects while improving patient compliance and dosage effectiveness by controlling drug release through the skin. The barrier function of the skin, especially the stratum corneum, can interfere with drug delivery. Few drugs can pass through the skin to reach effective concentrations in the blood to treat diseases. Due to their unique physicochemical properties and high potential to reduce immunogenicity and improve bioavailability, BC-dermal/transdermal DDSs are widely used to deliver various types of drugs for disease treatment. In this review, we describe the different types of BC-dermal/ transdermal DDSs, along with a critical discussion of the advantages and disadvantages of these systems. After the general presentation, the review is focused on recent advances in the preparation and applications of BC-based dermal/transdermal DDSs in various types of disease treatment.

Novel technologies for applying immune checkpoint blockers

Cancer cells develop several ways to subdue the immune system among others via upregulation of inhibitory immune checkpoint (ICP) proteins. These ICPs paralyze immune effector cells and thereby enable unfettered tumor growth. Monoclonal antibodies (mAbs) that block ICPs can prevent immune exhaustion. Due to their outstanding effects, mAbs revolutionized the field of cancer immunotherapy. However, current ICP therapy regimens suffer from issues related to systemic administration of mAbs, including the onset of immune related adverse events, poor pharmacokinetics, limited tumor accessibility and immunogenicity. These drawbacks and new insights on spatiality prompted the exploration of novel administration routes for mAbs for instance peritumoral delivery. Moreover, novel ICP drug classes that are adept to novel delivery technologies were developed to circumvent the drawbacks of mAbs. We therefore review the state-of-the-art and novel delivery strategies of ICP drugs.